[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Estramustine.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Estramustine.]
[L04AA27, fingolimod, Estramustine may increase the immunosuppressive activities of Fingolimod.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Estramustine.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Estramustine.]
[L01CB02, teniposide, The risk or severity of adverse effects can be increased when Teniposide is combined with Estramustine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Tetracaine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Estramustine.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Estramustine is combined with Eribulin.]
[L01AC01, thiotepa, The risk or severity of adverse effects can be increased when Estramustine is combined with Thiotepa.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Estramustine.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Estramustine.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Estramustine.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Estramustine.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Estramustine is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Estramustine.]
[J01FA08, troleandomycin, The metabolism of Estramustine can be decreased when combined with Troleandomycin.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Estramustine.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Belimumab.]
[A10BH05, linagliptin, The metabolism of Estramustine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Estramustine can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Estramustine can be decreased when combined with Telaprevir.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Estramustine is combined with Belatacept.]
[C08DA01, verapamil, The metabolism of Estramustine can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Estramustine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The risk or severity of adverse effects can be increased when Vinblastine is combined with Estramustine.]
[L01CA02, vincristine, The risk or severity of adverse effects can be increased when Vincristine is combined with Estramustine.]
[L01CA03, vindesine, The risk or severity of adverse effects can be increased when Vindesine is combined with Estramustine.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Estramustine.]
[J05AE02, indinavir, The metabolism of Estramustine can be decreased when combined with Indinavir.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Estramustine is combined with Brentuximab vedotin.]
[L01ED01, crizotinib, The metabolism of Estramustine can be decreased when combined with Crizotinib.]
[N05AE04, ziprasidone, The metabolism of Estramustine can be decreased when combined with Ziprasidone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Estramustine.]
[L01EJ01, ruxolitinib, The risk or severity of adverse effects can be increased when Estramustine is combined with Ruxolitinib.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Estramustine.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Estramustine.]
[J02AC03, voriconazole, The metabolism of Estramustine can be decreased when combined with Voriconazole.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Estramustine is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Estramustine.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Estramustine.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Azathioprine is combined with Estramustine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Estramustine.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Estramustine.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Estramustine.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Estramustine.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Estramustine is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Estramustine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Estramustine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Estramustine can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The risk or severity of adverse effects can be increased when Estramustine is combined with Bosutinib.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Estramustine is combined with Teriflunomide.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Estramustine is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Estramustine is combined with Aldosterone.]
[J05AE04, nelfinavir, The metabolism of Estramustine can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Bendamustine.]
[L04AA29, tofacitinib, Estramustine may increase the immunosuppressive activities of Tofacitinib.]
[L01EA05, ponatinib, The risk or severity of adverse effects can be increased when Estramustine is combined with Ponatinib.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Estramustine is combined with Pomalidomide.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Estramustine is combined with Dimethyl fumarate.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Benzocaine.]
[L04AA18, everolimus, The risk or severity of adverse effects can be increased when Estramustine is combined with Everolimus.]
[L01EC02, dabrafenib, The serum concentration of Estramustine can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Benzyl alcohol.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Estramustine is combined with Ibrutinib.]
[J05AP05, simeprevir, The metabolism of Estramustine can be decreased when combined with Simeprevir.]
[A16AA07, metreleptin, The metabolism of Estramustine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Estramustine is combined with Apremilast.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Estramustine.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Estramustine is combined with Siltuximab.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Vedolizumab.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Estramustine is combined with Belinostat.]
[L01EM01, idelalisib, The risk or severity of adverse effects can be increased when Estramustine is combined with Idelalisib.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Estramustine is combined with Peginterferon beta-1a.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Estramustine is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Estramustine is combined with Pirfenidone.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Estramustine is combined with Blinatumomab.]
[L01XK01, olaparib, The risk or severity of adverse effects can be increased when Estramustine is combined with Olaparib.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Secukinumab.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Estramustine is combined with Palbociclib.]
[L01XH03, panobinostat, The risk or severity of adverse effects can be increased when Estramustine is combined with Panobinostat.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Estramustine.]
[L01CX01, trabectedin, The risk or severity of adverse effects can be increased when Estramustine is combined with Trabectedin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Mepolizumab.]
[J02AC05, isavuconazole, The metabolism of Estramustine can be decreased when combined with Isavuconazole.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Ixekizumab.]
[L01XX52, venetoclax, The metabolism of Estramustine can be decreased when combined with Venetoclax.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Bupivacaine.]
[L01AB01, busulfan, The risk or severity of adverse effects can be increased when Busulfan is combined with Estramustine.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Estramustine.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Estramustine can be decreased when combined with Ribociclib.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Ocrelizumab.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Oxybuprocaine.]
[A12AA04, calcium carbonate, Calcium carbonate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Estramustine.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Estramustine.]
[J05AE09, tipranavir, The metabolism of Estramustine can be decreased when combined with Tipranavir.]
[D11AX03, calcium gluconate, Calcium gluconate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Estramustine.]
[A12AA01, calcium phosphate, Calcium Phosphate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EX10, midostaurin, The metabolism of Estramustine can be decreased when combined with Midostaurin.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Sarilumab.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Capecitabine is combined with Estramustine.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Estramustine is combined with Vorinostat.]
[J05AG03, efavirenz, The metabolism of Estramustine can be decreased when combined with Efavirenz.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Estramustine.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Estramustine.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Estramustine is combined with Budesonide.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Capsaicin.]
[L02BB05, apalutamide, The metabolism of Estramustine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Estramustine.]
[A06AC08, calcium polycarbophil, Calcium polycarbophil can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Estramustine.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Estramustine is combined with Baricitinib.]
[L01XX62, ivosidenib, The metabolism of Estramustine can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Estramustine can be decreased when combined with Stiripentol.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Chloroprocaine.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Estramustine.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Ravulizumab.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Estramustine is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Estramustine can be decreased when combined with Clarithromycin.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Estramustine is combined with Cloprednol.]
[V03AE07, calcium acetate, Calcium acetate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Estramustine.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Estramustine is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Risankizumab.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Estramustine is combined with Upadacitinib.]
[N07XX11, pitolisant, The serum concentration of Estramustine can be decreased when it is combined with Pitolisant.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Estramustine is combined with Deflazacort.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Estramustine.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Estramustine is combined with Trastuzumab emtansine.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Estramustine is combined with Diroximel fumarate.]
[N03AX25, cenobamate, The serum concentration of Estramustine can be decreased when it is combined with Cenobamate.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Teprotumumab.]
[J05AE05, amprenavir, The metabolism of Estramustine can be decreased when combined with Amprenavir.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Estramustine is combined with Ozanimod.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Estramustine.]
[C01BD07, dronedarone, The metabolism of Estramustine can be decreased when combined with Dronedarone.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Estramustine.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Estramustine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Estramustine.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Estramustine is combined with Fluprednidene.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Estramustine is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Estramustine is combined with Stepronin.]
[L04AC19, satralizumab, The serum concentration of Estramustine can be decreased when it is combined with Satralizumab.]
[B06AC06, berotralstat, The metabolism of Estramustine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Estramustine can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Fludarabine is combined with Estramustine.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Estramustine is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Estramustine can be increased when it is combined with Abametapir.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Estramustine.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Estramustine is combined with Ponesimod.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Estramustine.]
[L01XX73, sotorasib, The serum concentration of Estramustine can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Estramustine can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of adverse effects can be increased when Cisplatin is combined with Estramustine.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Estramustine is combined with Pegcetacoplan.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Estramustine is combined with Belumosudil.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Anifrolumab.]
[N06AX25, St. John's wort extract, The metabolism of Estramustine can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Estramustine is combined with Ropeginterferon alfa-2b.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Levobupivacaine.]
[C01EB24, mavacamten, The serum concentration of Estramustine can be decreased when it is combined with Mavacamten.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Estramustine is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Estramustine is combined with Deucravacitinib.]
[N05AH02, clozapine, The metabolism of Estramustine can be decreased when combined with Clozapine.]
[H01AC08, somatrogon, The metabolism of Estramustine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Bimekizumab.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Estramustine is combined with Leflunomide.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Estramustine is combined with Nelarabine.]
[J01FA15, telithromycin, The metabolism of Estramustine can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Estramustine is combined with Ciclesonide.]
[J02AC02, itraconazole, The metabolism of Estramustine can be decreased when combined with Itraconazole.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Estramustine.]
[J02AC04, posaconazole, The metabolism of Estramustine can be decreased when combined with Posaconazole.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Estramustine.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Estramustine is combined with Meprednisone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Estramustine.]
[L01AA01, cyclophosphamide, The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Estramustine.]
[S01XA18, cyclosporine, Estramustine may increase the immunosuppressive activities of Cyclosporine.]
[C03XA02, conivaptan, The metabolism of Estramustine can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Cytarabine is combined with Estramustine.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Estramustine.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Dactinomycin is combined with Estramustine.]
[G03XA01, danazol, The metabolism of Estramustine can be decreased when combined with Danazol.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Estramustine.]
[N06AX06, nefazodone, The metabolism of Estramustine can be decreased when combined with Nefazodone.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Estramustine.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Estramustine.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Estramustine.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Estramustine is combined with Dexamethasone.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Estramustine.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Cinchocaine.]
[M05BA02, clodronic acid, The serum concentration of Estramustine can be increased when it is combined with Clodronic acid.]
[L01DC04, ixabepilone, The risk or severity of adverse effects can be increased when Estramustine is combined with Ixabepilone.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Estramustine is combined with Pirarubicin.]
[C08CA03, isradipine, The metabolism of Estramustine can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Estramustine is combined with Difluocortolone.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Estramustine.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Estramustine.]
[J05AE08, atazanavir, The metabolism of Estramustine can be decreased when combined with Atazanavir.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Estramustine can be decreased when combined with Diltiazem.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Diphenhydramine.]
[S01XA23, sirolimus, The risk or severity of adverse effects can be increased when Sirolimus is combined with Estramustine.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Natalizumab.]
[S02AA12, rifamycin SV, The metabolism of Estramustine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Estramustine can be increased when combined with Rifapentine.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Estramustine.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Ropivacaine.]
[L01EX01, sunitinib, The risk or severity of adverse effects can be increased when Estramustine is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Estramustine can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The risk or severity of adverse effects can be increased when Bortezomib is combined with Estramustine.]
[L01DB01, doxorubicin, The risk or severity of adverse effects can be increased when Doxorubicin is combined with Estramustine.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Estramustine is combined with Corticotropin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Estramustine.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Estramustine.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Estramustine is combined with Trofosfamide.]
[L01CA04, vinorelbine, The risk or severity of adverse effects can be increased when Vinorelbine is combined with Estramustine.]
[C08CA12, mepirodipine, The metabolism of Estramustine can be decreased when combined with Barnidipine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Estramustine.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Estramustine.]
[N02CA02, ergotamine, The metabolism of Estramustine can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The metabolism of Estramustine can be decreased when combined with Erythromycin.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Estramustine is combined with Antilymphocyte immunoglobulin (horse).]
[S01AA13, fusidic acid, The metabolism of Estramustine can be decreased when combined with Fusidic acid.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Estramustine.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Estramustine is combined with Fluticasone furoate.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Estramustine is combined with Fluticasone.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Etidocaine.]
[L01CB01, etoposide, The risk or severity of adverse effects can be increased when Etoposide is combined with Estramustine.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Estramustine.]
[R06AX12, terfenadine, The metabolism of Estramustine can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Estramustine can be decreased when combined with Fluvoxamine.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Estramustine.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Estramustine.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Estramustine.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Estramustine.]
[J02AC01, fluconazole, The metabolism of Estramustine can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Flucytosine is combined with Estramustine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Estramustine.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Estramustine.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Estramustine is combined with Fluocortolone.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Estramustine.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Estramustine.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Estramustine.]
[J05AE10, darunavir, The metabolism of Estramustine can be decreased when combined with Darunavir.]
[L01EA02, dasatinib, The risk or severity of adverse effects can be increased when Estramustine is combined with Dasatinib.]
[A12AA13, calcium citrate, Calcium citrate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12AA10, calcium gluceptate, Calcium glucoheptonate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12AA05, calcium lactate, Calcium lactate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EX02, sorafenib, The risk or severity of adverse effects can be increased when Sorafenib is combined with Estramustine.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Estramustine.]
[L01CE02, irinotecan, The risk or severity of adverse effects can be increased when Irinotecan is combined with Estramustine.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Estramustine.]
[C08CA10, nilvadipine, The metabolism of Estramustine can be decreased when combined with Nilvadipine.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Estramustine is combined with Hydroxychloroquine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Estramustine.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Idarubicin is combined with Estramustine.]
[L01AA06, ifosfamide, The risk or severity of adverse effects can be increased when Ifosfamide is combined with Estramustine.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Estramustine is combined with Paclitaxel.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Estramustine is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Topotecan is combined with Estramustine.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Estramustine.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Estramustine.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Estramustine.]
[N06AX17, milnacipran, The metabolism of Estramustine can be decreased when combined with Milnacipran.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Articaine.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Estramustine.]
[J04AC01, isoniazid, The metabolism of Estramustine can be decreased when combined with Isoniazid.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Tocilizumab.]
[J02AB02, ketoconazole, The metabolism of Estramustine can be decreased when combined with Ketoconazole.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Estramustine is combined with Abatacept.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Estramustine.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Lidocaine.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Estramustine is combined with Lomustine.]
[C10AA02, lovastatin, The metabolism of Estramustine can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The risk or severity of adverse effects can be increased when Estramustine is combined with Temsirolimus.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Estramustine is combined with Pralatrexate.]
[L01EA03, nilotinib, The metabolism of Estramustine can be decreased when combined with Nilotinib.]
[L01AA05, mechlorethamine, The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Estramustine.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Melphalan is combined with Estramustine.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Mepivacaine.]
[H03BB02, methimazole, The metabolism of Estramustine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Estramustine.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Estramustine.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Estramustine.]
[S02AA13, miconazole, The metabolism of Estramustine can be decreased when combined with Miconazole.]
[L01XX23, mitotane, The metabolism of Estramustine can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Estramustine is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Estramustine.]
[C01BD01, amiodarone, The metabolism of Estramustine can be decreased when combined with Amiodarone.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Estramustine is combined with Certolizumab pegol.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Ofatumumab.]
[L01EX03, pazopanib, The risk or severity of adverse effects can be increased when Estramustine is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Estramustine.]
[N03AB05, fosphenytoin, The metabolism of Estramustine can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Estramustine.]
[V03AB15, naloxone, The metabolism of Estramustine can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Estramustine.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Estramustine.]
[L01CD02, docetaxel, The risk or severity of adverse effects can be increased when Estramustine is combined with Docetaxel.]
[N06AX23, desvenlafaxine, The metabolism of Estramustine can be decreased when combined with Desvenlafaxine.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Estramustine.]
[C08CA04, nicardipine, The metabolism of Estramustine can be decreased when combined with Nicardipine.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Estramustine is combined with Rilonacept.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Estramustine is combined with Paramethasone.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Estramustine.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Estramustine.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Estramustine.]
[N05CA01, pentobarbital, The metabolism of Estramustine can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Estramustine.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Estramustine.]
[N03AA02, phenobarbital, The metabolism of Estramustine can be increased when combined with Phenobarbital.]
[N03AB02, phenytoin, The metabolism of Estramustine can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Golimumab.]
[J05AE01, saquinavir, The metabolism of Estramustine can be decreased when combined with Saquinavir.]
[J05AG02, delavirdine, The metabolism of Estramustine can be decreased when combined with Delavirdine.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Estramustine can be increased when it is combined with Ritonavir.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Estramustine.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Estramustine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Estramustine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Estramustine can be increased when combined with Primidone.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Estramustine is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Estramustine.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Estramustine.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Estramustine.]
[J04AB02, rifampin, The metabolism of Estramustine can be increased when combined with Rifampicin.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Estramustine.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Estramustine is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Estramustine.]
[L01CD04, cabazitaxel, The risk or severity of adverse effects can be increased when Estramustine is combined with Cabazitaxel.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Estramustine.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Estramustine is combined with Hydrocortisone butyrate.]
[H02CA04, levoketoconazole, The metabolism of Estramustine can be decreased when combined with Levoketoconazole.]
[A12AA11, calcium pangamate, Calcium pangamate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
